Securities Times e Company Newsgober168slotOn May 5, Hanyu Pharmaceutical (300199) said in response to investors 'questions on the interactive platform that in terms of research and development of synthetic biology and peptides, the company has reached a tripartite agreement with the Shenzhen Advanced Institute of the Chinese Academy of Sciences and the Shenzhen Institute of Science and Technology in 2022 to jointly build the "Joint Research Center for Synthetic Biology and Peptide Drugs" to cooperate on the research of polypeptide drugs such as diabetes, obesity, anti-infection, and anti-tumor. Research on candidate polypeptide drugs will be carried out based on candidate development varieties of polypeptide drugs or polypeptide drug varieties that need to be improved urgently, synthetic biology methods will be used, combined with rational design, molecular optimization and high-throughput screening platforms. So far, the joint research center is using synthetic bio-related technologies to construct and screen strains that highly express semigroutide propeptide. Combined with the company's unique chemical modification technology, the joint research center aims to provide large-scale and low-cost raw materials, optimize accessibility issues, and prepare for further expanding the international market.